Form 4: Replimune Director Receives 44,500 Stock Options

Director Veleka Peeples-Dyer was granted 44,500 stock options with a $7.61 exercise price, vesting in full by April 2027.

Summary

• Veleka Peeples-Dyer, a member of the Board of Directors, was granted 44,500 stock options on April 1, 2026.
• The options carry an exercise price of $7.61 per share.
• The grant is scheduled to vest in its entirety on April 1, 2027.
• The options have a ten-year term, expiring on April 1, 2036.
• The disclosure was filed on April 7, 2026, which was noted as a late filing due to an administrative error.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing for director compensation, though the late submission is a minor compliance negative.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.
• The exercise price of $7.61 establishes a clear baseline for future growth expectations.

Negatives

• The Form 4 was filed late, indicating a minor administrative oversight in regulatory compliance.

Risks

• Future exercise of these options will result in the issuance of 44,500 new shares, causing minor dilution to existing shareholders.
• The value of the compensation is entirely dependent on the stock price exceeding $7.61 by the time of vesting and exercise.

Future Outlook

The director's options will vest fully in April 2027, providing a one-year incentive window for corporate performance and strategic oversight.

Management Comments

• This Form 4 is being filed late due to inadvertent administrative error.

Industry Context

StockSavvy.ai notes that equity grants are a standard component of director compensation in the biotechnology sector, used to preserve cash while incentivizing board members to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant of 44,500 options is consistent with director compensation packages at peer biotechnology firms of similar market capitalization.
• A one-year cliff vesting schedule is a common practice for annual director equity awards in the U.S. market to ensure short-to-mid-term alignment.

Corporate Governance

Related Party Transactions

• Grant of 44,500 stock options to Director Veleka Peeples-Dyer as part of standard board compensation.

Stakeholder Impact

• Shareholders may face minor dilution upon the eventual exercise of these options.
• The director is incentivized to improve company performance to ensure the options remain valuable.

Next Steps

• Vesting of 44,500 options on April 1, 2027.

Key Dates

Keywords

Replimune Group, REPL, Insider Trading, Stock Options, Director Compensation, Biotechnology, Veleka Peeples-Dyer